ArticleClinical cancer research : an official journal of the American Association for Cancer Research2024

Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models.

Sheryl M Gough et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.